Cargando…

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

INTRODUCTION: Pegloticase, a PEGylated recombinant porcine uricase, is approved for treating refractory gout at a dose of 8 mg intravenous (IV) every 2 weeks. However, during phase 1 testing, pharmacokinetics supported less frequent dosing. Also, single doses of pegloticase unexpectedly induced anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hershfield, Michael S, Ganson, Nancy J, Kelly, Susan J, Scarlett, Edna L, Jaggers, Denise A, Sundy, John S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060462/ https://www.ncbi.nlm.nih.gov/pubmed/24602182 http://dx.doi.org/10.1186/ar4500

Ejemplares similares

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
por: Ganson, Nancy J, et al.
Publicado: (2006)

Long-term safety of pegloticase in chronic gout refractory to conventional treatment
por: Becker, Michael A, et al.
Publicado: (2013)

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
por: Lipsky, Peter E, et al.
Publicado: (2014)

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
por: Baraf, Herbert S. B., et al.
Publicado: (2014)

Impact of pegloticase on patient outcomes in refractory gout: current perspectives
por: Cunha, Rita N, et al.
Publicado: (2018)

A Case Report of Successful Management of Refractory Polyarticular Gout With Pegloticase
por: Alnabwani, Dina, et al.
Publicado: (2022)

New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012)

Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023)

Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer
por: Ganson, Nancy J., et al.
Publicado: (2015)

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout
por: Calabrese, Leonard H., et al.
Publicado: (2017)

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
por: Baraf, Herbert SB, et al.
Publicado: (2013)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
por: Mandell, Brian F., et al.
Publicado: (2018)

Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study
por: Chen, Sarah K, et al.
Publicado: (2020)

Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
por: Masri, Karim Richard, et al.
Publicado: (2022)

Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
por: Morton, Allan H., et al.
Publicado: (2018)

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study
por: Albert, John A., et al.
Publicado: (2020)

Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
por: Broadwell, Aaron, et al.
Publicado: (2022)

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
por: Botson, John K., et al.
Publicado: (2022)

Polyethylene Glycol‐Like Brush Polymer Conjugate of a Protein Drug Does Not Induce an Antipolymer Immune Response and Has Enhanced Pharmacokinetics than Its Polyethylene Glycol Counterpart
por: Ozer, Imran, et al.
Publicado: (2022)

Synthesis and Characterization of Polyethylene Glycol-Grafted Photoreactive Polyethylene Glycols for Antibiofouling Applications
por: Othman, Mahmoud H., et al.
Publicado: (2022)

Bactericidal activity of propylene glycol, glycerine, polyethylene glycol 400, and polyethylene glycol 1000 against selected microorganisms
por: Nalawade, Triveni Mohan, et al.
Publicado: (2015)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
por: Botson, John K., et al.
Publicado: (2022)

PEG-ing down (and preventing?) the cause of pegloticase failure
por: Abeles, Aryeh M
Publicado: (2014)

Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes
por: Hsieh, Yuan-Chin, et al.
Publicado: (2018)

Synthesis of Stable Cholesteryl–Polyethylene Glycol–Peptide Conjugates with Non-Disperse Polyethylene Glycol Lengths
por: Cristóbal-Lecina, Edgar, et al.
Publicado: (2020)

Polyethylene Glycol 3350 With Electrolytes Versus Polyethylene Glycol 4000 for Constipation: A Randomized, Controlled Trial
por: Bekkali, Noor L.H., et al.
Publicado: (2018)

Refractory Gout Attack
por: Fargetti, Simone, et al.
Publicado: (2012)

A genome-wide association study identifies a novel susceptibility locus for the immunogenicity of polyethylene glycol
por: Chang, Chia-Jung, et al.
Publicado: (2017)

Polyethylene glycol as a cause of anaphylaxis
por: Wylon, Katharina, et al.
Publicado: (2016)

Polyethylene Glycol Camouflaged Earthworm Hemoglobin
por: Jani, Vivek P., et al.
Publicado: (2017)

Effects of polyethylene glycol content on the properties of a silk fibroin/nano-hydroxyapatite/polyethylene glycol electrospun scaffold
por: Qi, Qi, et al.
Publicado: (2019)

On the Behavior of the Ethylene Glycol Components of Polydisperse Polyethylene Glycol PEG200
por: Hoffmann, Markus M., et al.
Publicado: (2023)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

A brush-polymer conjugate of exendin-4 reduces blood glucose for up to five days and eliminates poly(ethylene glycol) antigenicity
por: Qi, Yizhi, et al.
Publicado: (2016)

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
por: Botson, John K., et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
por: Botson, John K., et al.
Publicado: (2023)

The application of polyethylene glycol (PEG) to electron microscopy
Publicado: (1980)

Polyethylene glycolated PAMAM dendrimers-Efavirenz conjugates
por: Pyreddy, Suneela, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u9p0beibf5kdnev41ghusus1ba